Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Haydn T. Kissick"'
Autor:
Yuan Liu, Julie M. Shabto, Bradley C. Carthon, Lauren Yantorni, Viraj A. Master, Dylan J. Martini, Omer Kucuk, Kenneth Ogan, Mehmet Asim Bilen, Shreyas S. Joshi, Jacqueline T. Brown, Deepak Ravindranathan, Wayne Harris, Sarah Caulfield, Haydn T. Kissick, Emilie Elise Hitron, Greta Russler
Publikováno v:
Oncologist
Background The modified Glasgow prognostic score (mGPS), a clinical tool that incorporates albumin and C-reactive protein, has proven useful in the prognostication of multiple cancers. Several immune checkpoint inhibitors (ICIs) have been approved fo
Autor:
Xu Wang, Haydn T. Kissick, Andreas Wieland, Nabil F. Saba, Mihir R. Patel, William H. Hudson, Rafi Ahmed, Christiane S Eberhardt, Zhuo Georgia Chen, Maria Cardenas, Christopher C. Griffith, Rebecca C. Obeng
Publikováno v:
Nature. 597:274-278
Tumours often contain B cells and plasma cells but the antigen specificity of these intratumoral B cells is not well understood1-8. Here we show that human papillomavirus (HPV)-specific B cell responses are detectable in samples from patients with HP
Autor:
Mehmet Asim Bilen, Yuan Liu, Sarah Caulfield, Julie M. Shabto, Bradley C. Carthon, Viraj A. Master, Wayne Harris, Omer Kucuk, Dylan J. Martini, Haydn T. Kissick, Greta Russler, Emilie Elise Hitron
Publikováno v:
The Oncologist
Background The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria are the gold standard for risk‐stratifying patients with metastatic renal cell cancer (mRCC). We developed a novel risk scoring system for patients wit
Autor:
David H. Lawson, Haydn T. Kissick, R. Donald Harvey, Jacqueline T. Brown, Colleen Lewis, Olatunji B. Alese, Ragini R. Kudchadkar, Bassel F. El-Rayes, Mehmet Asim Bilen, Walid L. Shaib, Christina Wu, Amir Ishaq Khan, Yuan Liu, Julie M. Shabto, Hannah Collins, Rathi N. Pillai, Suresh S. Ramalingam, Milton Williams, Alexandra Speak, Viraj A. Master, Dylan J. Martini, Conor E. Steuer, Bradley C. Carthon, Mehmet Akce, Taofeek K. Owonikoko
Publikováno v:
The Oncologist
Oncologist
Oncologist
Background Sarcopenia and inflammation have been associated with poor survival in patients with cancer. We explored the combined effects of these variables on survival in patients with cancer treated with immunotherapy. Methods We performed a retrosp
Autor:
Jeremy M. Boss, Edmund K. Waller, Sanjay Chandrasekaran, David A. Gutman, Christopher D. Scharer, Dillon G. Patterson, Kelly R. Magliocca, Sergei V. Kotenko, Lee Ad Cooper, Gregory B. Lesinski, Brian Pollack, Carlos S. Moreno, John T. Seykora, Susan N. Thomas, Robert A. Swerlick, Maiko Sasaki, Haydn T. Kissick, Bishu Sapkota
Publikováno v:
Mol Cancer Res
Molecular events activating the PI3K pathway are frequently detected in human tumors and the activation of PI3K signaling alters numerous cellular processes including tumor cell proliferation, survival, and motility. More recent studies have highligh
Autor:
Milton Williams, Viraj A. Master, Olatunji B. Alese, David H. Lawson, Christina Wu, Ragini R. Kudchadkar, Hannah Collins, Yuan Liu, Amir Ishaq Khan, Dylan J. Martini, Conor E. Steuer, Haydn T. Kissick, Mehmet Akce, Bradley C. Carthon, Bassel F. El-Rayes, R. Donald Harvey, Colleen Lewis, Julie M. Shabto, Suresh S. Ramalingam, Taofeek K. Owonikoko, Meredith R Kline, Mehmet Asim Bilen, Rathi N. Pillai, Walid L. Shaib
Publikováno v:
Cancer. 126:575-582
BACKGROUND Body mass index (BMI) is used to define obesity, but it is an imperfect measure of body composition. In the current study, the authors explored the association between types of fat and survival in patients treated with immunotherapy. METHO
Autor:
Dylan J. Martini, T. Anders Olsen, Subir Goyal, Yuan Liu, Sean T. Evans, Benjamin Magod, Jacqueline T. Brown, Lauren Yantorni, Greta Anne Russler, Sarah Caulfield, Jamie M. Goldman, Bassel Nazha, Haydn T. Kissick, Wayne B. Harris, Omer Kucuk, Bradley C. Carthon, Viraj A. Master, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
BackgroundImmune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). Biomarkers for mRCC patients treated with ICI are limited, and body composition is underutilized in mRCC. We investigated the as
Autor:
Wayne Harris, Bradley C. Carthon, Shreyas S. Joshi, Julie M. Shabto, Deepak Ravindranathan, Jacqueline T. Brown, Omer Kucuk, Sarah Caulfield, Kenneth Ogan, Dylan J. Martini, Viraj A. Master, Haydn T. Kissick, Lauren Yantorni, Emilie Elise Hitron, Mehmet Asim Bilen, Yuan Liu, Greta Russler, Bassel Nazha
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
BackgroundThe modified Glasgow Prognostic Score (mGPS) is a composite biomarker that uses albumin and C reactive protein (CRP). There are multiple immune checkpoint inhibitor (ICI)-based combinations approved for metastatic renal cell carcinoma (mRCC
Autor:
Wayne Harris, Lauren Yantorni, Jamie M. Goldman, Subir Goyal, Katherine Case, Sean Evans, Viraj A. Master, Greta Russler, Haydn T. Kissick, Bassel Nazha, T. Anders Olsen, Benjamin Magod, Yuan Liu, Mehmet Asim Bilen, Dylan J. Martini, Bradley C. Carthon, Omer Kucuk, Sarah Caulfield, Jacqueline T. Brown
Publikováno v:
Oncologist
Background Immune checkpoint inhibitors (ICIs) are an important treatment for metastatic renal cell carcinoma (mRCC). These agents may cause immune-related adverse events (irAEs), and the relationship between irAEs and outcomes is poorly understood.
Autor:
Mehmet Asim Bilen, Haydn T. Kissick, Bassel F. El-Rayes, Bradley C. Carthon, Christina Wu, Hannah Collins, Walid L. Shaib, Mehmet Akce, Yuan Liu, Olatunji B. Alese, Viraj A. Master, Ragini R. Kudchadkar, Julie M. Shabto, Suresh S. Ramalingam, Dylan J. Martini, Conor E. Steuer, Rathi N. Pillai, Taofeek K. Owonikoko, David H. Lawson, R. Donald Harvey, Colleen Lewis
Publikováno v:
Cancer. 125:127-134
BACKGROUND Optimal prognostic and predictive biomarkers for patients with advanced-stage cancer patients who received immunotherapy (IO) are lacking. Inflammatory markers, such as the neutrophil-to-lymphocyte ratio (NLR), the monocyte-to-lymphocyte r